Balyasny Asset Management LLC Anavex Life Sciences Corp. Transaction History

Balyasny Asset Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$3.39 - $5.02 $199,098 - $294,829	-58,731 Reduced 70.69%	24,349 $102,000
Q1 2024 May 13, 2024	BUY	$4.55 - $6.75 $62,694 - $93,008	13,779 Added 19.88%	83,080 $422,000
Q4 2023 Feb 14, 2024	BUY	$5.04 - $9.95 $221,911 - $438,098	44,030 Added 174.23%	69,301 $645,000
Q3 2023 Nov 14, 2023	SELL	$6.55 - $9.37 $123,677 - $176,924	-18,882 Reduced 42.76%	25,271 $165,000
Q2 2023 Aug 14, 2023	BUY	$7.66 - $9.5 $106,305 - $131,841	13,878 Added 45.84%	44,153 $358,000
Q1 2023 May 15, 2023	SELL	$8.32 - $11.75 $238,833 - $337,295	-28,706 Reduced 48.67%	30,275 $259,000
Q4 2022 Feb 14, 2023	BUY	$7.65 - $14.43 $14,412 - $27,186	1,884 Added 3.3%	58,981 $546,000
Q3 2022 Nov 14, 2022	BUY	$8.9 - $12.86 $508,163 - $734,267	57,097 New	57,097 $589,000
Q4 2017 Feb 14, 2018	SELL	$3.12 - $4.94 $45,601 - $72,203	-14,616 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$3.42 - $4.87 $49,986 - $71,179	14,616	14,616 $61,000

161

27.4M

515K

838K

Ticker AVXL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,942,800
Market Cap $818M
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.